Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vaxart, Inc. - Common Stock (NQ:VXRT)

0.7020 +0.1650 (+30.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vaxart, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2021
Upgrades UBS upgraded the previous rating for ONE Gas Inc (NYSE: 
Via Benzinga
Don’t Write Off Vaxart, As Its Oral Vaccine Still Has a Chance
Vaxart stock is still worth a shot, as there's still big potential demand for a "no-needle" Covid-19 vaccine alternative. 
Via InvestorPlace
Exposures COVID-19
Can This COVID Vaccine Stock Help Make You Rich?
This biotech has a nifty trick potentially up its sleeve. 
Via The Motley Fool
Exposures COVID-19
Unusual Options Activity Insight: Vaxart
Vaxart (NASDAQ:VXRT) shares experienced unusual options ac... 
Via Benzinga
Unusual Options Activity Insight: Vaxart
Shares of Vaxart (NASDAQ:VXRT) saw some unusual options a... 
Via Benzinga
Why Ocugen Stock Is Rallying While Moderna, Novavax, Vaxart Can't Catch Up
Ocugen Inc. (NASDAQ:OCGN) shares were trading higher Tuesd... 
Via Benzinga
NASDAQ:VLDR Shareholder Notice: Update in Lawsuit Against Velodyne Lidar, Inc.
San Diego, CA -- (SBWIRE) -- 10/12/2021 -- An update was announced in the lawsuit that was filed for certain investors in shares of Velodyne Lidar, Inc. (NASDAQ:VLDR). 
Via SBWire
Topics Lawsuit
Exposures Financial Legal
NASDAQ:VXRT Investor Alert: Update in Lawsuit Against Vaxart, Inc.
San Diego, CA -- (SBWIRE) -- 10/12/2021 -- An update was announced in the lawsuit that was filed for certain investors in shares of Vaxart, Inc. (NASDAQ:VXRT). 
Via SBWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
Vaxart May Be a COVID Vaccine Game Changer -- but Is It Too Late?
The company is working on a vaccine candidate that doesn't involve a needle. 
Via The Motley Fool
Why Vaxart Shares Are Trading Higher Today
Vaxart Inc (NASDAQ: VXRT) is trading higher Friday after the company reported a Duke University-led study published in bioRxiv showed that the company's investigational... 
Via Benzinga
18 Stocks Moving in Friday's Pre-Market Session
Gainers eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) rose 25.5% to $14.41 in pre-market trading after the company, in collaboration with investigators at Baylor College of Medicine... 
Via Benzinga
Why Vaxart Shares Are Surging In Thursday's After-Hours Session
Vaxart Inc (NASDAQ: VXRT) is surging higher in after-hours trading Thursday after the company reported a Duke University-led study published in bioRxiv showed that the... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Vaxart (NASDAQ:VXRT) shares incr... 
Via Benzinga
Why Vaxart Stock Tumbled in September
A COVID-19 antiviral pill may undermine the biotech's value proposition. 
Via The Motley Fool
Exposures COVID-19
Vaxart Starts Recruitment In Mid-Stage COVID-19 Oral Vaccine Trial
Vaxart Inc (NASDAQ: VXRT) has begun recruiting subjects for its Phase 2 COVID-19 oral tablet vaccine clinical trial. Related: FDA Clears Vaxart's... 
Via Benzinga
Exposures COVID-19 Product Safety
Why Investing in VXRT Stock is a Coin Flip
Vaxart is a gamble for biotechnology investors, with its upside too dependent on the approval of an oral vaccine. 
Via InvestorPlace
Exposures COVID-19
What's Going On With Vaxart's Stock?
Vaxart Inc. (NASDAQ: VXRT) shares traded higher Tuesday after a study titled "A Phase 2 Trial With an Oral Tableted Covid-19 Vaccine" was posted to Clinicaltrials.gov.... 
Via Benzinga
Exposures COVID-19
Vaccine Stocks: Why MRNA, VXRT, CVAC and NVAX Stocks Need a Band-Aid Today
Today, vaccine stocks are taking a massive hit as investors price in the potential effect of oral medications for Covid-19 on this sector. 
Via InvestorPlace
Exposures COVID-19
Vaxart Traders Should Not Dismiss the Vaccine Maker’s Momentum
The recently range-bound price action of VXRT stock doesn't reflect the progress that Vaxart is making against Covid-19. 
Via InvestorPlace
As the Virus Continues, the Global Covid-19 Vaccine Market Expected to Reach $25 Billion By 2024
Via FinancialNewsMedia
Exposures COVID-19
It’s Time to Start Thinking Seriously About Vaxart
While VXRT stock is risky due to underlying clinical challenges, the evolving nature of Covid-19 makes it worth consideration. 
Via InvestorPlace
Topics Government
Exposures COVID-19 Political
Vaxart Looks To Be On The Verge Of Breaking Out Of A Pattern
Vaxart Inc. (NASDAQ: VXRT) shares are trading lower Monday, possibly after retail traders were able to push the stock higher. The stock looks to be almost breaking out of a... 
Via Benzinga
Vaxart Stock Is One Vaccine Also-Ran Worth Another Look
The jury's out whether its oral Covid-19 vaccine will be successful, but VXRT stock may still be worth it as a speculative play. 
Via InvestorPlace
Exposures COVID-19
Is Vaxart Stock Really Worth a Shot?
VXRT stock still has hope as Vaxart is developing modern rDNA vaccines in pill form (including a Covid-19 vaccine). 
Via InvestorPlace
Exposures COVID-19
Longshot Covid Play Vaxart Stock Is Too Risky at These Prices
Vaxart got approval Aug. 2 for a Phase II trial for its oral Covid-19 vaccine. VXRT stock has gained since, but it's still too pricey. 
Via InvestorPlace
Exposures COVID-19
Vaxart Is Another Risky Biotech Stock to Avoid Right Now
VRXT stock is highly overvalued. Investors are holding out for its Covid-19 vaccine, but it may not be approved in time to boost shares. 
Via InvestorPlace
Exposures COVID-19
The Delta Variant Is a Shot in the Arm for Vaxart’s Pill Vaccine
With many unvaccinated and the Delta variant a growing danger, VXRT stock has a good chance to increase in value in the coming future. 
Via InvestorPlace
Exposures COVID-19
Vaxart Stock Probably Isn’t Worth the Risk as It Pushes Higher
Vaxart’s oral recombinant vaccines are an interesting approach. Whether they do anything for VXRT stock remains to be seen. 
Via InvestorPlace
Why Shares of Vaxart Are Soaring Today
Some encouraging news for this troubled biotech. 
Via The Motley Fool
Exposures COVID-19
28 Stocks Moving in Friday's Pre-Market Session
Gainers Sphere 3D Corp. (NASDAQ: ANY) shares rose 35.4% to $4.66 in pre-market trading after the company reported an Agreement to acquire exclusive rights for assignment of... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.